Related Experiment Video
Updated: May 11, 2026

In Vivo Imaging to Measure Spontaneous Lung Metastasis of Orthotopically-injected Breast Tumor Cells
Published on: June 23, 2022
[Providing information about metastasised cancer could be better: time for a good talk]
1Radboud Universitair Medisch Centrum, afd. Medische Oncologie, Nijmegen. w.vandergraaf@onco.umcn.nl
Abstract:
It has been suggested that clinical oncologists do not discontinue active treatment in the palliative setting in a timely manner, and only care about the extension rather than the quality of life. Moreover, patients may be not very well informed about their prognosis and the intention behind their treatment. To improve decision-making in the palliative phase, understanding of recent advances in cancer care should be shared, as well as any potential adverse effects. Decision aids may be useful to improve the chance of satisfactory treatment decisions. The desire to obtain information is high in the majority of patients; however, oncologists do not always provide enough key information, particularly in terms of survival. During consultations, the time available to discuss these aspects is limited; it is believed that allocating more time for outpatient consultations could improve the quality and satisfaction regarding the decision to treat or not to treat. Ideally, general practitioners and palliative teams should be involved early in the decision-making process.
More Related Videos
Related Concept Videos
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Cancer Survival Analysis
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Treatment Resistant Cancers

